Perinatal Substance Exposure Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About Perinatal Substance Exposure
Perinatal substance exposure occurs when a baby is exposed to drugs or alcohol during pregnancy. This can lead to various health challenges for the newborn, requiring specialized care and often expensive medications. TheDrugClub helps families manage these costs, ensuring access to vital prescriptions for both mother and child at affordable rates.
Understanding Perinatal Substance Exposure
Perinatal substance exposure refers to the period surrounding childbirth, specifically when a baby is exposed to substances like opioids, cannabis, stimulants, or alcohol while in the womb. This exposure can significantly impact fetal development and lead to various health issues for the newborn. One of the most recognized conditions resulting from opioid exposure is Neonatal Abstinence Syndrome (NAS) or Neonatal Opioid Withdrawal Syndrome (NOWS), where babies experience withdrawal symptoms shortly after birth.
Beyond immediate withdrawal, perinatal substance exposure can contribute to a range of long-term challenges, including developmental delays, behavioral issues, and learning difficulties as the child grows. It's crucial to understand that this condition is a complex medical and social issue, requiring empathy and support rather than judgment. The focus is always on providing the best possible care for both the mother and the baby to promote healthy outcomes.
Treatments and Medications for Perinatal Substance Exposure
Treatment for babies affected by perinatal substance exposure often begins in the neonatal intensive care unit (NICU). For NAS/NOWS, medications such as morphine, methadone, or buprenorphine may be used to gradually wean the baby off the substance, managing severe withdrawal symptoms. Alongside medication, supportive care is vital, including creating a low-stimulation environment, providing frequent small feedings, and comforting techniques like swaddling.
As children grow, they may require ongoing therapies such as physical, occupational, or speech therapy to address developmental delays. Early intervention programs are also key to supporting their learning and behavioral development. For mothers, treatment often involves substance use disorder programs, including Medication-Assisted Treatment (MAT) like buprenorphine/naloxone or
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.